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PCR-based immunoglobulin (Ig)/T-cell receptor (TCR) clonality testing in suspected lymphoproliferations has largely been
standardized and has consequently become technically feasible in a routine diagnostic setting. Standardization of the pre-analytical
and post-analytical phases is now essential to prevent misinterpretation and incorrect conclusions derived from clonality data.
As clonality testing is not a quantitative assay, but rather concerns recognition of molecular patterns, guidelines for reliable
interpretation and reporting are mandatory. Here, the EuroClonality (BIOMED-2) consortium summarizes important pre- and
post-analytical aspects of clonality testing, provides guidelines for interpretation of clonality testing results, and presents a uniform
way to report the results of the Ig/TCR assays. Starting from an immunobiological concept, two levels to report Ig/TCR proﬁles are
discerned: the technical description of individual (multiplex) PCR reactions and the overall molecular conclusion for B and T cells.
Collectively, the EuroClonality (BIOMED-2) guidelines and consensus reporting system should help to improve the general
performance level of clonality assessment and interpretation, which will directly impact on routine clinical management
(standardized best-practice) in patients with suspected lymphoproliferations.
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INTRODUCTION
The diagnosis of lymphoid malignancies is greatly supported and
facilitated by clonality testing. Depending on the experience of
the hematopathologists and the type of histopathological
requests, 5–15% of cases could beneﬁt from molecular clonality
diagnostics.1,2 Of the many different markers that can be used for
clonality testing in suspected lymphoproliferations, immuno-
globulin (Ig) and T-cell receptor (TCR) antigen receptor gene
rearrangements stand out as the most widely applied targets.
These Ig and TCR rearrangements are formed from the earliest
stages of B-cell and T-cell development onwards.3,4 Random
coupling between one of many V, (D) and J genes results in
the formation of a unique V(D)J exon that encodes the actual
antigen-binding moiety of the Ig or TCR chain. Owing to the huge
diversity in Ig/TCR rearrangements, the diversity of different Ig or
TCR molecules is estimated to be in the order of 1012. As a
consequence each lymphocyte has a unique antigen receptor
molecule on its membrane and the chance that two different
lymphocytes coincidentally bear the same receptor is almost
negligible. Hence, identical rearrangements are not derived from
multiple independently generated cells, but rather reﬂect the
clonal nature of the involved cell population. Evaluation of the
homogeneous vs heterogeneous nature of the rearrangements is
thus at the basis of clonality testing.
In the last two decades, PCR-based analysis of Ig/TCR
rearrangements has gradually replaced Southern blot analysis as
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gold standard method for clonality testing.1,5–14 However, the
earliest PCR strategies suffered from false negativity (lack of
recognition of all possible rearrangements) and false positivity
(inability to accurately distinguish monoclonal from polyclonal
PCR products). False negativity was at least in part also caused by
the fact that most laboratories only used TCR gamma (TCRG) and
complete IG heavy chain (IGH) V–J gene rearrangements as PCR
targets for reasons of limited primer usage and relatively simple
gene structure. These drawbacks prompted the design of
completely novel assays for Ig/TCR rearrangement detection in
the European BIOMED-2 network (now called EuroClonality
consortium).15 This effort has resulted in standardized multiplex
PCR assays for nearly all Ig/TCR targets, which collectively show an
unprecedentedly high rate of detection in the most common
B- and T-cell malignancies.2,16–18 This high detection rate was not
only achieved by optimized primer design, but also by inclusion of
extra Ig/TCR targets (IG kappa, IGK and TCR beta, TCRB as well as
incomplete IGH D–J and TCRB D–J rearrangements).15 Meanwhile,
the BIOMED-2/EuroClonality PCR protocols have been extensively
validated in studies of many groups outside the consortium.19–22
As a result these multiplex assays have now become the world
standard for PCR-based Ig/TCR clonality testing.
Owing to the successful development of the BIOMED-2/
EuroClonality multiplex PCR protocols, the analytical phase of
clonality testing has thus largely been standardized. Because of
this standardization, Ig/TCR clonality testing has now become
technically feasible in a routine diagnostic setting. This is
reinforced by the availability of commercial kits to run these
assays (InVivoScribe, San Diego, CA, USA). An important con-
sequence of the technical standardization and commercialization
is that clonality assays can easily be performed in routine
laboratories, even in (smaller) laboratories that only occasionally
receive clonality testing requests, and thus have limited experi-
ence. However, background knowledge and ample experience are
more than ever required for Ig/TCR target choice and accurate
interpretation of the PCR results.23 In an attempt to make
interpretation less subjective, interpretation algorithms have
been introduced, especially in the United States.24–26 These
algorithms take into account peak heights and peak ratios to
deﬁne ‘truly clonal’ rearrangements. Although clear clones readily
fulﬁll such criteria, the cutoff values used in these algorithms
create a false sense of accuracy and might even lead to false-
positive or false-negative interpretation. The main problem is that
multiplex clonality PCRs, which use primers of different
efﬁciencies, are not quantitative, but merely qualitative assays.
Thus, clonality testing much more concerns recognition of
molecular patterns, for which accurate interpretation and
reporting guidelines are mandatory. Hence, standardization of
the pre-analytical and post-analytical phases is urgently needed to
prevent misinterpretation and incorrect conclusions of the
clonality data obtained.
For this reason standardization of interpretation and quality
control are major aims of the EuroClonality consortium, next to
education and further innovation in molecular hemato-oncology
(see: http://www.euroclonality.org). While setting up an external
quality assessment (EQA) scheme for Ig/TCR clonality testing, the
need for guidelines on how to interpret and report
Ig/TCR clonality data has become even more apparent, given
the lack of objective criteria to evaluate Ig/TCR data. During recent
years, the EuroClonality group has therefore been working on
standardization of pre- and post-analytical aspects, including the
development of clear guidelines for analysis, interpretation and
reporting of the EuroClonality (BIOMED-2) Ig/TCR assays.
Here, we discuss important pre- and post-analytical aspects of
clonality testing, provide guidelines for interpretation of clonality
results and present a uniform way to report the results of Ig/TCR
assays. Collectively, these aspects should help to improve the
general performance level of clonality assessment and
interpretation, which will directly impact on routine clinical
management (standardized best-practice) in patients with
suspected lymphoproliferations.
PRE-ANALYTICAL PHASE
In the pre-analytical phase several aspects are of utmost
importance for optimal clonality testing results. These include
the clinical context, selection of representative material, preserva-
tion and sample handling, isolation of nucleic acid (yield, purity
and integrity) and selection of Ig/TCR rearrangements as PCR
targets.
Material type and sample preparation
Particularly relevant for ﬁnal interpretation is key information on
the suspected cell population. This information should come from
either (histo)morphology/immunohistochemistry and/or ﬂow
cytometric immunophenotyping, and typically concerns the
suspected cell lineage and the tumor size, as well as the
background of non-suspicious (normal or reactive) lymphoid cells.
It is obvious that the performance of the multiplex Ig/TCR
clonality assays is highest with fresh or frozen cell material, as
these PCR assays have been validated and standardized for that
type of material. However, the use of formalin-ﬁxed parafﬁn-
embedded (FFPE) tissues has also proven to be a realistic option,27
provided that the DNA is not too degraded. Although most
nucleic acid isolation procedures (traditional methods and/or kits)
generally result in a good yield and purity, it might be important
to further purify the DNA isolated from FFPE blocks to remove PCR
inhibitors. Because of the inhibitory effect, it is advised to test FFPE
DNA at different concentrations (at least two) in the Ig/TCR
multiplex PCRs. In this respect, FFPE DNA integrity should be
checked upfront to adapt the concentration used in the Ig/TCR
assays. In contrast, for fresh-frozen tissues it is sufﬁcient to check
DNA integrity afterwards, only when unexpected negative results
are obtained in the Ig/TCR tests. DNA integrity can be checked via
one of many available PCRs that target a single gene. Though
these control tests might have their value, the BIOMED-2 control
gene test, being a multiplex assay of differently sized amplicons, is
preferred as it probably best reﬂects the multiplex conditions
under which the actual Ig/TCR clonality tests are run15 and
provides a good view of the product sizes that can be expected to
be ampliﬁed properly. Given the amplicon size of most Ig/TCR
targets, ampliﬁcation of fragments of 300 nucleotides (nt) in the
control PCR predicts reliable Ig/TCR testing results. Nevertheless,
even when amplicons of maximally 200 nt are obtained, smaller
Ig/TCR amplicons might still be evaluated reliably (Table 1).28
Selection of targets
Once the DNA quality is checked and approved, the next
important aspect of the pre-analytical phase concerns the
selection of the Ig/TCR targets to be evaluated. Target selection
typically depends on the amount of available DNA, the DNA
integrity and naturally the clinical question, including the type of
suspected cell population. If the DNA amount and integrity are not
limiting factors, target selection is solely determined by the clinical
question.
In the EuroClonality network, an algorithm for target selection
has been proposed that depends on the suspected cell population
(Figure 1).2 Thus, in case of suspected B-cell clonality, generally the
three different IGH FR targets are chosen, in parallel to or followed
by the IGK targets.17 Although the consecutive use of IGH and IGK
PCRs might be the more cost-efﬁcient approach,21 a parallel
approach is more time-efﬁcient for both the clinician and the
patient. Even though the combination of IGH V–J and IGK targets
should be sufﬁcient in the vast majority of cases (495%),
evaluation of the IGH D–J and IGL targets might occasionally be
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helpful as second-line approach.17 This should be applied to cases
with strong suspicion of B-cell clonality that is not conﬁrmed by
IGH V–J and IGK testing. Analogous to B cells, suspected T-cell
clonality can best be addressed by evaluating two TCR targets
(TCRB and TCRG), either in parallel or consecutively. Traditionally,
TCRG is the gold standard target, but our own results in the
EuroClonality network show that TCRB is at least equally
informative as ﬁrst-line target.16 Importantly, TCR delta (TCRD)
(generally together with TCRG) should only be used as a target for
well-deﬁned clinical requests, that is, suspected TCRgd T-cell
proliferations or immature (lymphoblastic) T-cell proliferations.2,16
Usage of TCRD in other situations merely creates difﬁculties due to
the fact that most TCRD rearrangements are removed in TCRab
lineage T cells upon rearrangement of the TCR alpha (TCRA) locus;
thus, the paucity of TCRD templates might easily give rise to
preferential ampliﬁcation and pseudoclonality. Moreover, even
authentic clonal TCRD rearrangements might not be associated to
a malignant lymphoid proliferation.29
Priority in selection of targets for cases with low DNA quality or
low DNA amount
In case of FFPE specimens with low-quality DNA, some targets
(IGH FR3, IGK V–J and TCRG) might still be optimal because of their
smaller amplicon size, whereas other targets with larger amplicons
(IGH FR1, IGH FR2, IGK Kde and TCRB) could be less reliable.
Nevertheless, ampliﬁcation of the targets with larger amplicons
might still be possible in some cases and should not be
discouraged upfront. For example, despite a size range of
210–400 nt for IGK Kde amplicons, IGK Kde PCR can be very
valuable, even in samples of suboptimal DNA quality.20–28
The priority of targets might not solely depend on amplicon
sizes. In case of suspected T-cell proliferations, some targets (TCRG
V–J tube B and TCRB D–J) are notoriously difﬁcult when evaluated
in isolation. Moreover, also the complementarity of the multiplex
PCRs will inﬂuence selection of targets that should be assessed in
duplicate. Thus, both TCRB V–J tubes and both TCRG V–J tubes
should preferably be analyzed in parallel. Hence, for suspected
T-cell proliferations with limited DNA amount and low DNA
quality, the recommended multiplex PCRs would be at least TCRG-
tube A and TCRB tube A preferably with TCRB tube B. For
suspected B-cell proliferations, target choice is based on amplicon
sizes but also on the type of suspected lymphoma. For (post-)
germinal center lymphomas, IGH D–J and IGK Kde are ideal PCR
targets as these are not prone to somatic mutations. However, it
should be stressed that for all cases with limited DNA integrity and
DNA amount, duplicate assessment of a single PCR tube is highly
preferred over testing multiple PCR targets.
Finally, for cases with a low percentage of suspected B or T cells,
reproducibility of the proﬁles is essential. A low number of
lymphocytes in, for example, skin or intestinal lesions can easily
result in overinterpretation of coincidental dominant peaks. To
prevent misinterpretation, assessment of the targets in duplicate
as well as adjustment of the amount of DNA by increasing the
DNA concentration, and hence the number of cells per PCR, are
strongly recommended.
POST-ANALYTICAL PHASE: PITFALLS AND SOLUTIONS
Accurate interpretation and reporting of clonality testing results
heavily depends on detailed knowledge on the structure of Ig/TCR
genes, their rearrangement patterns and awareness of all
nonspeciﬁc ampliﬁcations and cross-lineage rearrangements.
Many of these issues have been addressed extensively over the
years in multiple publications on behalf of the EuroClonality
group.23,30,31 Recently, even a whole issue of the Journal of
Hematopathology was devoted to multiple aspects of clonality
testing.27,28,32–37 Owing to their impact on interpretation and
reporting, the most relevant technical and immunobiological
pitfalls are brieﬂy discussed here (see also Table 2).
Technical pitfalls
If no PCR products (that is, neither clonal nor polyclonal products)
are obtained in the multiplex PCR, it is worth checking the
underlying reason, as this will have direct consequences for
Table 1. Ig/TCR multiplex PCR: preferred method of analysis, expected size ranges and nonspecific bandsa
Multiplex PCR Preferred method of analysis Size range (nt) Nonspecific bands (nt)
IGH VH–JH GS and HD both suitable Tube A: 310–360
Tube B: 250–295
Tube C: 100–170
Tube A: B85
Tube B: B228b
Tube C: B211b
IGH DH–JH HD slightly preferred over GS
(Amplicon variation hampers GS)
Tube D: 110–290 (DH1/2/4/5/6-JH)
390–420 (DH3–JH)
Tube E: 100–130
Tube D: B350c
Tube E: 211d
IGK GS and HD have complementary value
(Small CDR3þ amplicon variation hamper GS)
Tube A: 120–160 (Vk1f/6/Vk7-Jk)
190–210 (Vk3f-Jk)
260–300 (Vk2f/Vk4/Vk5-Jk)
Tube B: 210–250 Vk1f/6/Vk7-Kde 270–300
(Vk3f/intron-Kde)
350–390 (Vk2f/Vk4/Vk5-Kde)
Tube A: B217b
Tube B: B404b
IGL HD slightly preferred over GS
(Small CDR3 hampers GS)
Tube A: 140–165 Tube A:—
TCRB GS and HD both suitable Tube A: 240–285
Tube B: 240–285
Tube C: 170–210 (Db2) 285–325 (Db1)
Tube A: B213b,e, B273b
Tube B: B93, B126, B221b,e
Tube C: B128, B337b,e
TCRG GS and HD both suitable Tube A: 145–255
Tube B: 80–220
Tube A:—
Tube B:—
TCRD HD slightly preferred over GS
(Low template amountþ amplicon variation
hamper GS)
Tube A: 120–280 Tube A: B90, B123
Abbreviations: GS, GeneScan; HD, heteroduplex; Ig, immunoglobulin; IGH, IG heavy chain; IGK, IG kappa; IGL, IG lambda; nt, nucleotide; TCR, T-cell receptor;
TCRB, TCR beta; TCRD, TCR delta; TCRG, TCR gamma. aUpdate of table 25 of earlier BIOMED-2/EuroClonality report.15 bParticularly seen in samples with low
numbers of contaminating lymphoid cells. cNonspecific 350-bp band is the result of cross-annealing of the DH2 primer to a sequence upstream of JH4. In
GeneScanning this nonspecific band does not comigrate with D–J products. dThe 211-bp PCR product represents product from germline DH7–JH1 region;
when PCR amplification is very efficient, also longer PCR products might be obtained based on primer annealing to downstream JH genes; for example, 419 bp
(DH7–JH2), 1031bp (DH7–JH3), and so on.
eDetection of nonspecific band depends on quality of primers (batch-dependent).
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interpretation and alternative strategies. Lack of Ig/TCR (mono-
clonal and polyclonal) products because of poor DNA quality of
the FFPE tissue can be conﬁrmed by checking DNA quality in a
control gene multiplex PCR (see above). Furthermore, B- and T-cell
numbers can be rechecked using histological slides or ﬂow
cytometry data to understand whether the lack of detectable PCR
products is caused by lack of B or T cells in the sample. If so, an
alternative specimen should be analyzed. For B-cell clonality it is
important to verify whether the patient has received CD20
antibody therapy. Finally, extensive somatic mutation in Ig genes
might prevent optimal annealing of Ig primers and thus block
efﬁcient ampliﬁcation of the clonal Ig rearrangement. In such
cases, alternative Ig targets that are less prone to somatic
hypermutation (IGH D–J, IGK Kde rearrangements) should be
evaluated (concept of complementarity of targets).15,17,38 False-
negative results can also be caused by the presence of t(11;14)
and t(14;18) aberrations in mature B-cell proliferations. As these
aberrant IGH rearrangements are not ampliﬁed in the IGH
multiplex PCRs, an IGH V–J PCR failure could be expected from
such alleles. Thus, information concerning complementary labora-
tory tests (for example, ﬂuorescence in situ hybridization analysis)
should be taken into account when interpreting clonality data.
Based on primer positions and the expected extent of nt
insertion at the junctions, amplicon size ranges were previously
established for all Ig/TCR multiplex PCR reactions (Table 1).
However, as these size ranges represent the approximate 5–95%
intervals, amplicons that are a few nts shorter or longer may still
represent true rearrangements. Even clearly undersized or over-
sized amplicons may be considered as true rearrangements in the
absence of evidence of nonspeciﬁc products in other sam-
ples,36,39,40 especially in IGH and IGK targets that harbor deletions
and insertions through the somatic hypermutation process.41 Also,
ampliﬁcation from a downstream J gene might create extended
PCR amplicons, which could occur as an additional PCR product in
the same or the another V–J multiplex reaction (in case of TCRB,
IGH and IGK) or as the sole PCR product (in case of IGH and
IGK).36,42 In the latter situation, this is mostly due to disrupted
primer annealing to the J gene of the V(D)J junction owing to the
clonality
(generally multiple
clonal results)
Suspected lymphoid
proliferations of
unknown origin
(B or T)
Suspected B-cell
proliferations
Suspected T-cell
proliferations
IGH VH-JH
3 tubes
IGK Vκ-Jκ
IGK Kde
2 tubes
preferably with
TCRG
2 tubes
preferably with
TCRB Vβ-Jβ
TCRB Dβ-Jβ
3 tubes
and
no clonality
but still suspected
IGH DH-JH
and IGL
2 tubes 
TCRD
1 tube
clonality
probably polyclonality
(particularly in case of clear
Gaussian GeneScan profiles
or heteroduplex smears)
TCRγδ+ proliferations
or immature T-cells
Figure 1. Strategy for PCR-based clonality diagnostics in suspected lymphoproliferations with an inconclusive diagnosis or with unusual
histology, immunophenotype or clinical presentation, using the EuroClonality/BIOMED-2 multiplex PCR protocols. In case of a suspected B-cell
proliferation, IGH VH–JH multiplex PCR analysis is best performed first. As a second step, IGK PCR analysis (Vk–Jk and Kde rearrangements) can
be chosen. Preferably, these two steps are combined to avoid delay in the diagnostic process. Finally, IGH DH1-6–JH PCR analysis (potentially
combined with IGL analyses) can be reserved for remaining suspected cases, in which the preceding PCR assays have failed to detect
monoclonality and have not shown clear signs of polyclonality either. For suspected T-cell proliferations, TCRB multiplex PCR is generally
slightly more informative than TCRG PCR, but the order of analysis of these two loci can be changed as they provide complementary
information; preferably both targets should be used in parallel. Only in case of suspected TCRgdþ T-cell proliferations and immature T-cell
proliferations (suspicion of lymphoblastic malignancies), combined TCRG and TCRD PCR analysis is preferred. In case of suspected
lymphoproliferations of unknown origin, both Ig and TCR genes should be used as PCR targets. It should be noted that in such cases the
clonal Ig/TCR results cannot be used straightforwardly for B-/T-lineage assignment. A full-proof diagnosis of polyclonality remains difficult, but
a high probability of polyclonality is supported by clear Gaussian GS curves or HD smears in the absence of clonal results.
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somatic mutations. Furthermore, in some cases multiple peaks/
bands are observed that result from the same IGK V–J rearrange-
ment, which is explained by some cross-annealing of V family-
speciﬁc primers to genes of other V families and the fact that
these V primers are not clustered.15
Finally, a general technical pitfall of multiplex PCR reactions
is that they run a higher risk of nonspeciﬁc ampliﬁcation than
monoplex PCR. This especially holds for those samples in which
competition for true Ig/TCR templates is limited due to low
numbers of B or T cells. Though several of these nonspeciﬁc
amplicons have been described before, recently some novel
nonspeciﬁc products have been found. Therefore, we have now
updated the original information of the 2003 publication in
Table 1.
Biological pitfalls
Beside the technical issues, also multiple biological pitfalls
can pose difﬁculties in interpretation of clonality testing results.
These pitfalls not only concern immunobiological aspects, but also
locus-intrinsic aspects.
Translating the number of apparently clonal peaks into the
number of clones is not always straightforward. Most lymphocytes
undergo rearrangements on both alleles of a particular Ig or TCR
locus. Hence, two clonal peaks are more likely to reﬂect biallellic
rearrangement patterns than biclonality.43 Nonetheless, true
biclonality can occur in up to 5% of mature B-cell
lymphoproliferative disorders, and in these cases careful
interpretation of IGH/IGK rearrangement patterns must be
performed in conjunction with morphology, immunophenotyping
Table 2. Technical and biological pitfalls in Ig/TCR clonality testing
Phenomenon Pitfall Potential solution
Lack of clonal signal and lack of polyclonal
Gaussian curve
1. Poor DNA quality
2. Few T/B cells
3. Clonal signal not detected due to SHM in
malignant cells
1. Check DNA quality in control PCR
2. Check T-/B-cell content by histology or flow
cytometry
3. Evaluate other framework or Ig target
Bands/peaks outside size range 1. CDR3 regions/junctions outside 5–95%
size interval
2. Nonspecific product
1. True rearrangement product; in case of doubt,
sequence for confirmation
2. Check Table1 for sizes of nonspecific products
Undersized bands/peaks For example, internal deletion in VH/Vk/Vl
gene (SHM related)
Potential rearrangement product; sequence for
confirmation
Oversized bands/peaks For example, extended amplification from
downstream J gene (for example, due to
SHM in rearranged JH gene)
Potential rearrangement product; sequence for
confirmation
Multiple clonal signals Bi-allelic rearrangements
Biclonality
Consider the number of potential rearrangements
per allele/locusa and judge whether this fits with
clonality (with biallelic rearrangements) or
biclonality
Selective amplification and pseudoclonality,
due to low level of specific template
Few T/B cells in sample Repeat multiple PCRs (same tissue, second
independent DNA isolation and/or related tissue)
-compare patterns for consistency
Oligo-/monoclonality in histologically
reactive lesion
Exaggerated immune response with
dominant specificity (for example, large
germinal centers)
1. Repeat multiple PCRs (same tissue, second
independent DNA isolation and/or related tissue)
-compare patterns for consistency between
samples and multiple targets
2. Re-evaluate histopathology
Oligoclonal T-/(B)-cell repertoire in
peripheral blood of elderly individuals,
immunodeficient patients or transplant
patients
Incomplete immune system, for example,
in case of immunosenescence or reduced/
suppressed lymphocyte production
Repeat multiple PCRs (same tissue, second
independent DNA isolation and/or related tissue)
-compare patterns for consistency and compare
with primary process (in case of staging)
Abbreviations: CDR, complementarity-determining region; HD, heteroduplex; Ig, immunoglobulin; IGK, IG kappa; SHM, somatic hypermutation; TCR, T-cell
receptor; TCRB, TCR beta. aIn TCRB and IGK loci multiple rearrangements can be detectable per allele, which influences the number of peaks/bands that is
compatible with a single clone.35 Complex patterns may be seen after HD analysis.
Table 3. Typical expected Ig/TCR profiles under different immunobiological conditions
Immunobiological condition Examples Expected profile in PCR reaction
No lymphocytes Non-hematopoietic tissue No peaks/bands (w/o background)a
Paucity of lymphocytes Small infiltrate, small sample (for example, skin) (Minor) peaks/bands, not reproducible
(Immune)activation with dominant clones Dominant immune response (for example,
infection, autoimmunity)
(Multiple) peaks/bands, reproducible
Reactive lymphocytes Broad immune response (Irregular) Gaussian curve/smear
Monoclonality (mono-/bi-allelic) Leukemia, lymphoma, (clone of unknown significance)b One or two peaks/bandsc
Monoclonalityþpolyclonal background Idem,(small) clone between normal/reactive lymphocytesb One or two peaks/bandscþGaussian
curve/smear
Monoclonality (somatically mutated) Idem, (post-)follicular B-cell process No peaks/bandsd (or Gaussian curve/smear
from remaining normal lymphocytes)a
Abbreviations: Ig, immunoglobulin; IGK, IG kappa; TCR, T-cell receptor; TCRB, TCR beta. aNonspecific peak(s)/band(s) might be observed. bClone of unknown
significance is mostly seen under conditions in which there is some residual background of polyclonal cells. cNumber of peaks/bands is dependent upon
competition in PCR reaction; for IGK and TCRB loci up to four clonal products may be compatible with one clone. dRepresents false-negative result.
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and/or immunohistochemistry.43,44 Furthermore, because of the
speciﬁc conﬁguration of some Ig/TCR loci (especially IGK and
TCRB), multiple rearrangements can be present on the same allele.
Consequently, this will have an impact on deﬁning the number of
clones, as the presence of up to four different IGK or TCRB
rearrangements is still compatible with a single clonal cell
population (explained in detail in Langerak et al.35).
Additional immunobiological aspects to be considered when
interpreting Ig/TCR clonality data, have to do with the number of
lymphocytes, in the sample and with the immune reactivity under
inﬂammatory or ageing conditions. The presence of only few B or
T cells in the sample (for example, in skin tissues) might cause
preferential ampliﬁcation, leading to the false impression of
monoclonality (pseudoclonality). This stresses the importance
of evaluating duplicate PCR reactions to establish reproducibility
of clonality patterns and products. Under certain conditions
(infection and inﬂammation) multiple clonal peaks might be
present as a result of an exaggerated immune response. These
immune response-related clonal expansions of lymphocyte
populations should not be misinterpreted as signs of malig-
nancy.18,45 Detection of an oligoclonal T-cell repertoire in the
blood of elderly individuals and immunodeﬁcient patients or
transplant patients should be considered as potential sign of an
incomplete immune system due to ageing of the system
(immunosenescence) and reduced or suppressed T-cell
production, respectively.1 The same might apply to the B-cell
repertoire in an ageing immune system, though possibly to a
lesser extent.
EXTERNAL QUALITY ASSESSMENT
To ensure correct performance and accurate interpretation of
results in laboratories performing Ig/TCR clonality assays, a robust
EQA scheme is an essential instrument. The initial challenge was
therefore to standardize EQA for clonality analysis among
EuroClonality laboratories and to develop guidelines for analysis,
interpretation and reporting of clonality testing results.
In the ﬁrst ﬁve EQA rounds that were organized in the
EuroClonality network, the performance of BIOMED-2-based
Ig/TCR clonality assessment was tested using DNA samples
from different hematological and histopathological cases.46 As
readout systems both GeneScan (GS) fragment analysis and
polyacrylamide heteroduplex (HD) analysis were used.15 Cases in
the various EQA rounds were selected by the individual EQA
round organizers to include both classical lymphoproliferations as
well as more difﬁcult cases. Each center processed the diagnostic
DNA according to their routine PCR workﬂow dependent on the
suspected diagnosis. For several EQA rounds, these DNA samples
were accompanied by data ﬁles of GS analysis proﬁles and
photographic images of HD gels, which were evaluated by the
participants. These electronic data ﬁles and images allowed a
more accurate assessment of the reproducibility of interpretation
Table 4. The EuroClonality uniform system for technical description
Type of profile per tube (in duplicate) Technical description per tube Optional: more detailed technical
descriptiona
No peaks/bands (but: poor DNA quality) No (specific) product, poor DNA
quality
No peaks/bands (w/o background) No (specific) product Nonspecific product(s) (y nt)
One or two reproducible clonal peaks/bandsb Clonal (y nt) Weak clonal (y nt)
Clonal (y nt)þpolyclonal
background
(Gaussian curve/smear)
One or two non-reproducible (clear) peaks/bandsb Pseudoclonal
Multiple (nX3) non-reproducible peaks/bandsb Pseudoclonal
Multiple (nX3) reproducible peaks/bandsb Multiple products (n¼ y) (y nt)
Gaussian curve/smearc (with or without minor reproducible
peaks/bandsb)
Polyclonal (not clonalc) Irregular polyclonal (not clonalc)
Pattern that cannot be categorized as one of the above Not evaluabled
Abbreviations: HD, heteroduplex; nt, nucleotide. aExamples of more detailed technical description options that can be chosen by the user. bIn HD analysis the
number of bands does not necessarily reflect the number of different PCR products, as additional HDs can be formed between products. cIn HD analysis a
polyclonal smear may not always be smooth or clear, despite specific product in gel; hence this is scored as ‘not clonal’. dIno5% of PCR results the description
per tube cannot be made.
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Figure 2. Example highlighting the difficulty to correlate the number of bands in HD analysis to the number of rearrangements. Using TCRG
multiplex PCR tube A, two clonal peaks are observed (biallelic rearrangements) in GS analysis (a). In contrast, in HD analysis (b) four bands are
seen, two representing the homoduplexes of B144 and B216 bp, and the other two representing clonal HDs between the two clonal
rearrangements (indicated by arrows).
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and reporting of the data, as in these electronic EQA rounds
variation in the analytical phase was eliminated.46
EUROCLONALITY UNIFORM DESCRIPTION AND REPORTING OF
IG/TCR DATA
The post-analytical phase of diagnostic PCR-based clonality testing
comprises three different levels, (1) technical description per PCR;
(2) overall molecular interpretation of clonality testing data
(separate for Ig and TCR); and (3) integration of the clonality
testing results with morphological, immunophenotypical and
clinical data. Therefore, from the ﬁrst EQA round onwards, a
process of developing a standardized technical description of
individual multiplex tubes (level 1) was started. In the later EQA
rounds the uniform technical description was further reﬁned to a
standardized reporting system. In parallel, reporting of the overall
molecular interpretation of Ig and TCR clonality data (level 2)
was also standardized. As clinical interpretation is dependent
upon morphological, immunophenotypical and/or clinical data,
standardization of level 3 was considered to be beyond the scope
of EuroClonality. Finally, the revised standardized description
system was evaluated by each EuroClonality center using 50
consecutive routine diagnostic cases that were submitted for Ig/
TCR clonality testing.
Immunobiological concept as starting point
To create a conceptual basis for the proposed EuroClonality
uniform description and reporting of clonality data, we ﬁrst
deﬁned the typical Ig/TCR proﬁles that could be expected in
particular immunobiological conditions (Table 3). Notably, repro-
ducibility of the proﬁles is an important aspect of this conceptual
basis. We therefore strongly advocate the use of duplicates
(independent PCR ampliﬁcations from the same DNA isolate, or
from a second DNA isolate), such that results from the duplicate
analyses can be taken into account. In our view and experience
having the results from duplicate experiments is pivotal for
accurate interpretation of the molecular proﬁles.
In DNA samples from a specimen without lymphocytes, no
rearranged Ig/TCR genes are to be expected. This implies that in
such samples no speciﬁc Ig/TCR amplicons can be formed,
however, it should be realized that nonspeciﬁc PCR products of
the multiplex assays might become more easily ampliﬁed in such
samples (Table 1). When few lymphocytes are present in the
specimen (so called paucicellular specimens), for example, in a
case of a small lymphocyte inﬁltrate in a skin sample, selective
ampliﬁcation might occur. This is due to a nonrandom distribution
of DNA template in the aliquot that is used in the PCR reaction.
The resulting Ig/TCR proﬁle will show several peaks or bands that
are not reproducible in duplicates. In specimens with numerous
reactive lymphocytes an Ig/TCR proﬁle with a more or less
complete Gaussian distribution is to be expected, whereas a
dominant immune response might create (multiple) peaks/bands
that are reproducible in duplicates. Finally, the presence of a
monoclonal population of lymphocytes, as in a lymphoid
malignancies or as a clone of unknown signiﬁcance, is predicted
to give rise to one or two clear (reproducible) peaks or bands
(monoallelic and mostly biallelic rearrangements, respectively),
possibly in combination with a polyclonal Gaussian proﬁle of the
non-clonal reactive lymphocytes. It should be noted that for some
targets (IGH, TCRB and TCRG) the presence of clear monoclonal
peaks/bands in one multiplex PCR reaction might result in lack of
speciﬁc Ig/TCR amplicons in the complementary multiplex PCR
targeting the same locus, owing to the lack of remaining reactive
lymphocytes. An exceptional situation could be expected in the
case of B-cell clones that show a heavy somatic mutation load, in
which case the monoclonal product would remain undetected
resulting in a Gaussian Ig proﬁle (when reactive cells are present in
the background) or a proﬁle without Ig peaks/bands (in case of a
high tumor load without reactive cells).
Technical description of individual multiplex PCR reactions
Based on the expected proﬁles presented in Table 3, we deﬁned a
list of technical descriptions for the expected proﬁles (level 1 of
post-analytical interpretation). These technical descriptions are
primarily meant to standardize reporting and interpretation within
and between laboratories. Nevertheless, these descriptions some-
times appear on the ﬁnal report to the clinician or pathologist. At
ﬁrst we started with an extensive list of technical descriptions
taking into account all kind of subtleties, but gradually this list
shortened, as it appeared to be too difﬁcult to ﬁnd consensus on
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Figure 3. Examples of technical descriptions of different IGH GS
profiles. Representative examples of profiles are shown for IGH
multiplex tube A. All assays have been performed in duplicate, but
owing to space constraints duplicates are only shown for some
technical descriptions in which the reproducibility of the pattern is
crucial for proper choice of the term.
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distinguishing between several of the more subtle terms. After
four EQA rounds, we therefore agreed to make a more limited
series of consensus technical descriptions that should clearly
distinguish between the main proﬁles of the multiplex PCRs
(Table 4). To describe additional aspects of the proﬁles, we agreed
to have the option of a more detailed description in addition to
the main description category. The uniform system for technical
descriptions was intended for both GS fragment analysis and gel-
based HD analysis, however, it appeared that some of the options
are clearly applicable to GS analysis but are not very suitable for
describing HD results (Table 4).
When applying these descriptions in daily practice, proﬁles
without peaks/bands will be referred to as ‘no (speciﬁc) product’,
with the possibility to indicate that DNA quality appeared to be
poor. Optionally, nonspeciﬁc PCR products and their amplicon
sizes are mentioned. Proﬁles with one or two clear peaks or bands
are called ‘clonal’, with the option to indicate that the intensities
are weak or that a polyclonal background is seen. Even cases that
show a relatively weak clonal peak/band in a polyclonal back-
ground can be truly clonal, as long as the pattern is reproducible
and preferably seen in multiple targets. When one to two peaks or
bands are identiﬁed that are clearly non-reproducible, this is
referred to as ‘pseudoclonal’; implicit in this description is that
clonal signals are seen, but that they differ in size between the
duplicates. Proﬁles with multiple (deﬁned as three or more) peaks
or bands are indicated with the description ‘multiple products’.
Such proﬁles can be non-reproducible or reproducible; the former
option is very close to ‘pseudoclonal’, whereas the latter reﬂects
multiple consistent clones probably due to a dominant immune
response. It should be noted that in HD analysis the number of
bands is not necessarily equal to the number of rearrangements
due to the presence of both homoduplex band(s) as well as HD
band(s) formed between the different rearrangements (Figure 2).
The Gaussian proﬁle in GS analysis and the smear in HD analysis
are described as ‘polyclonal’, although the HD smear may not
always be clearly visible in which case this proﬁle is best referred
to as ‘not clonal’. If the Gaussian distribution is not perfectly
shaped (especially in GS analysis), the option ‘irregular polyclonal’
can be used to more accurately describe a proﬁle that is largely
polyclonal with some minor peaks. Finally, any proﬁle that cannot
be categorized as one of these categories should be referred to as
‘not evaluable’. One example might be those proﬁles in which the
signal intensity is in the range of background noise.
To illustrate the main technical descriptions of the various
Ig/TCR proﬁles in GS analysis, we have selected several routine
diagnostic cases that showed representative proﬁles for one or
more of the Ig/TCR loci (Figures 3–8).
Molecular conclusion on Ig/TCR gene rearrangement pattern
Based upon the results of the individual PCR targets and using the
knowledge of the Ig/TCR loci, the molecular conclusion on the Ig/
TCR rearrangement pattern is deﬁned.
Analogous to the list of technical descriptions, we also started
with a long list of overall molecular interpretations and conclu-
sions of clonality testing results (level 2 of post-analytical
interpretation). These molecular interpretations are based on the
technical descriptions of all available Ig/TCR proﬁles, dealing with
B and T cells separately. It should be noted that that cross-lineage
rearrangements may occur occasionally,16,17 and with high
frequency in immature lymphoid malignancies.47 After careful
evaluation in several EQA rounds a consensus system consisting of
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Figure 4. Examples of technical descriptions of different IGK GS profiles. Representative examples of profiles are shown for IGK multiplex
tube A. All assays have been performed in duplicate, but owing to space constraints duplicates are only shown for some technical descriptions
in which the reproducibility of the pattern is crucial for proper choice of the term.
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relatively few categories emerged (Table 5). Once again, the more
detailed conclusions are optional.
In case of poor DNA quality or if proﬁles in the Ig or TCR targets
are not evaluable, the overall conclusion is ‘not evaluable’. When
no speciﬁc products are seen in any of the Ig or TCR targets, the
overall molecular conclusion is ‘no rearrangements in Ig/TCR
targets detected’. Pseudoclonal proﬁles and proﬁles with multiple
non-reproducible products are grouped under the conclusion ‘no
clonality detected, suggestive of low template amount’. The other
three main categories of molecular conclusions are as follows:
‘clonality detected’, ‘oligoclonality/multiple clones detected’ and
‘polyclonality detected (or no clonality detected in case of weak or
faint smears in HD analysis)’. Each of these main conclusions
comes with one or more optional conclusions that contain more
details with respect to biallelic products, minor clonal products or
an oligo/polyclonal background. Importantly, the molecular
conclusion of ‘clonality detected’ can be made, even if not all
proﬁles show a clonal pattern.
Validation of the EuroClonality uniform description and reporting
system
We aimed to develop a description and reporting system that
should be applicable to495% of diagnostic cases. To validate the
uniform system presented here, each of the EuroClonality
laboratories scored 50 consecutive cases that were submitted
for routine Ig/TCR clonality testing in their institutes. In this way,
the system was evaluated on a total of41150 cases, representing
4750 B-cell clonality requests and 4620 T-cell clonality requests.
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Figure 5. Examples of technical descriptions of different TCRB (V–J)
GS profiles. Representative examples of profiles are shown for TCRB
multiplex tube B. All assays have been performed in duplicate, but
owing to space constraints duplicates are only shown for some
technical descriptions in which the reproducibility of the pattern is
crucial for proper choice of the term.
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Figure 6. Examples of technical descriptions of different TCRB (D–J)
GS profiles. Representative examples of profiles are shown for TCRB
multiplex tube C. All assays have been performed in duplicate, but
owing to space constraints duplicates are only shown for some
technical descriptions in which the reproducibility of the pattern is
crucial for proper choice of the term.
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Overall, the description and reporting system was difﬁcult to
apply in only 36/1150 (B3.1%) cases. Thus, applicability was
above the 95% target threshold, implying that the system works
well for routine clonality diagnostics in multiple centers that have
harmonized techniques and interpretation. Most of the difﬁculties
appeared to be centered around low-intensity clonal signals
resulting in a description of ‘clonality’ or ‘polyclonality’ with the
additional remark that a minor clone might be present. This is one
of the well-known gray areas in interpretation that will be hard to
completely standardize between centers.
CONTINUING MEDICAL EDUCATION THROUGH WORKSHOPS
Standardization and quality control is critically important for
optimizing clinical diagnostics for patient management. The other
important prerequisite for increasing quality of diagnostics is
continuous education, not only for new laboratories but also for
experienced users. Education is consequently another major aim
of the EuroClonality consortium. For this reason, annual educa-
tional workshops on clonality testing are organized for the
diagnostic community. These 3-day workshops are especially
meant for laboratories with some experience with the multiplex
PCR assays for Ig/TCR gene rearrangements that bring their
problematic cases for discussion. In addition, the workshop is also
relevant for those laboratories that have only just started to
perform PCR-based clonality testing in acquiring a broad under-
standing of the technical and biological pitfalls. Apart from
lectures on basic aspects on gene rearrangements and immuno-
biological and technical pitfalls of clonality testing, the main
purpose of these workshops is to have interactive sessions
between participants (pathologists or hematologists plus mole-
cular biologists) and faculty. In the various sessions of the
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Figure 7. Examples of technical descriptions of different TCRG GS
profiles. Representative examples of profiles are shown for TCRG
multiplex tube A. All assays have been performed in duplicate, but
owing to space constraints duplicates are only shown for some
technical descriptions in which the reproducibility of the pattern is
crucial for proper choice of the term.
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Figure 8. Examples of technical descriptions of different TCRD GS
profiles. Representative examples of profiles are shown for TCRD
multiplex tube. All assays have been performed in duplicate, but
owing to space constraints duplicates are only shown for some
technical descriptions in which the reproducibility of the pattern is
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workshop, difﬁcult cases with respect to histopathology and
molecular clonality data are presented by the participants
themselves, and interpretations are discussed. These multidisci-
plinary meetings perfectly illustrate the idea of an integrated
approach that is advocated to optimize interpretation of clonality
data. More details on the workshops can be found at the Euro-
Clonality website (http://www.euroclonality.org/workshop.html).48
FREQUENTLY ASKED QUESTIONS (FAQS) AND REVIEW OF
DIFFICULT CASES
A FAQs section is also present on the EuroClonality website. This
FAQs section contains a list of the most frequent issues from the
past years, ranging from ‘detection rate of clonality tests’ to
‘software used in clonality analysis’. The FAQs have been answered
by an expert team of molecular biologists routinely involved in
clonality testing in a pathological or immuno-hematological
setting. For questions that are not addressed in the FAQ section,
EuroClonality offers an online support service.48 To this end, a
Review Board of experts is available to respond to queries on
difﬁcult cases that pose trouble in interpretation. Scientists who
wish to use this service can upload their data ﬁles and query via
the EuroClonality website (http://www.euroclonality.org/Support.
php). Subsequently, teams of experts from the areas of hemato-
pathology and hematology–immunology will provide advice on
interpretation, reporting and further testing within 10 working
days. Many requests have been submitted to and addressed by
the Review Board, which clearly illustrates the role that such an
online service has in addition to publications, guidelines and
expert opinion papers.
CONCLUSION
Following earlier standardization of the analytical phase of Ig/TCR
clonality testing, the EuroClonality consortium now developed a
uniform reporting system for describing results and conclusions of
Ig/TCR clonality assays. At the outset several criteria were deﬁned
for the reporting system: (i) it should address two levels, that is, (a)
technical description of individual (multiplex) PCR results and (b)
overall molecular conclusion for B and T cells; (ii) it should be
useful for reporting both HD gel proﬁles and GS proﬁles; and (iii)
the system should be applicable to at least 95% of routine cases.
After validation in multiple EQA rounds and consequent ﬁnetun-
ing, we now have a consensus reporting system that fulﬁls all
these criteria. Clearly, two different levels are concerned with the
reporting system. To use the system in reporting both HD and GS
analysis results, we have deﬁned a successful approach, although
it should be stressed that some of the options are more difﬁcult to
apply to gels and will therefore be less commonly chosen for HD-
based results. This especially holds true for describing the number
of bands in HD analysis as there is a less direct relation between
the number of bands and the number of different rearrange-
ments, due to the presence of additional HDs between the
different rearrangements and due to single-strand DNA molecules.
Finally, we reached the predeﬁned aim to design reporting
guidelines that are applicable in 495% of routine diagnostic
cases, with only 3% of difﬁcult cases in a large cohort of 41150
routine cases that we studied within the EuroClonality consortium.
The uniform reporting system will also become available in other
languages via the website (http://www.euroclonality.org). It can
now be further validated in other EQA schemes and may
eventually be used to judge performance of individual labora-
tories in this type of diagnostics.
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Table 5. The EuroClonality uniform system for molecular conclusion
Overall technical description for all
Ig or TCR targets
Molecular interpretation/conclusion Optional: more detailed molecular interpretationa
No (specific) product, poor DNA quality Not evaluable, due to poor DNA quality
No (specific) product No rearrangement in Ig/TCR targets detected
Clonal (y nt)f Clonality detected Clonality detected (biallelic products)
Clonality detected (biclonality)
Clonality detected (minor clonal product)
Clonality detected (isolated rearrangement)
clonality detected
(with caution, plus advice for follow-up
analysis/new sample)
Clonality detected in addition to background
of B/T cells
Pseudoclonal (one or more
non-reproducible products)
No clonality detected, suggestive
of low template amount
Multiple reproducible products (nX3)b Oligoclonality/multiple clones detected Dominant clone in oligo/polyclonal background
Polyclonal (not clonalc) Polyclonality detected (no clonality detectedc) Polyclonality detected plus minor clone of
unknown significanced
Not evaluable Not evaluablee
Abbreviations: HD, heteroduplex; Ig, immunoglobulin; IGK, IG kappa; nt, nucleotide; TCR, T-cell receptor; TCRB, TCR beta. aExamples of more detailed molecular
interpretation options that can be chosen by the user. bFor IGK and TCRB loci up to four clonal products may be compatible with one clone. cIn HD analysis a
polyclonal smear may not always be clearly detectable, despite specific product in agarose gel; hence this is scored as ‘not clonal’. dFor those cases in which
minor reproducible peaks/bands are detected in the polyclonal background. eIn o5% of cases the molecular interpretation cannot be made. fClonal peaks/
bands are not necessarily seen for every Ig/TCR target analyzed to reach the molecular conclusion ‘clonality detected’.
EuroClonality/BIOMED-2 guidelines
AW Langerak et al
2169
& 2012 Macmillan Publishers Limited Leukemia (2012) 2159 – 2171
ACKNOWLEDGEMENTS
We gratefully acknowledge the technical support in the various laboratories of the
members of the EuroClonality consortium. We thank Mrs Sandra de Bruin-Versteeg
for help in preparing ﬁgures and Mrs Marieke Comans-Bitter for organizational
support for the EQA rounds.
REFERENCES
1 Van Dongen JJM, Wolvers-Tettero IL. Analysis of Ig and TCR genes, part II. Clin
Chim Acta 1991; 198: 93–174.
2 Van Krieken JHJM, Langerak AW, Macintyre EA, Kneba M, Smith JL, Garcia Sanz R
et al. Improved reliability of lymphoma diagnostics via PCR-based clonality test-
ing. Report of the BIOMED-2 Concerted Action BHM4-CT98-3936. Leukemia 2007;
21: 201–206.
3 Dik WA, Pike-Overzet K, Weerkamp F, De Ridder D, De Haas EF, Baert MRM et al.
New insights on human T-cell development by quantitative T-cell receptor
gene rearrangement studies and gene expression proﬁling. J Exp Med 2005; 201:
1715–1723.
4 Van Zelm MC, van der Burg M, de Ridder D, Barendregt BH, de Haas EF, Reinders
MJ et al. Ig gene rearrangement steps are initiated in early human precursor B cell
subsets and correlate with speciﬁc transcription factor expression. J Immunol
2005; 175: 5912–5922.
5 Van Dongen JJM, Hooijkaas H, Michiels JJ, Grosveld G, de Klein A, van der Kwast
TH et al. Richter’s syndrome with different immunoglobulin light chains and
different heavy chain gene rearrangements. Blood 1984; 64: 571–575.
6 Cleary ML, Chao J, Warnke R, Sklar J. Immunoglobulin gene rearrangement as a
diagnostic criterion of B-cell lymphoma. Proc Natl Acad Sci USA 1984; 81: 593–597.
7 Van Dongen JJM. Analysis of immunoglobulin genes and T cell receptor genes as
a diagnostic tool for the detection of lymphoid malignancies. Neth J Med 1987;
31: 201–209.
8 Deane M, Norton JD. Detection of immunoglobulin gene rearrangement in B
lymphoid malignancies by polymerase chain reaction gene ampliﬁcation. Br J
Haematol 1990; 74: 251–256.
9 Diss TC, Peng H, Wotherspoon AC, Isaacson PG, Pan L. Detection of monoclonality
in low-grade B-cell lymphomas using the polymerase chain reaction is dependent
on primer selection and lymphoma type. J Pathol 1993; 169: 291–295.
10 Wood GS, Tung RM, Haeffner AC, Crooks CF, Liao S, Orozco R et al. Detection of
clonal T-cell receptor gamma gene rearrangements in early mycosis fungoides/
Sezary syndrome by polymerase chain reaction and denaturing gradient gel
electrophoresis (PCR/DGGE). J Invest Dermatol 1994; 103: 34–41.
11 Theodorou I, Delfau-Larue MH, Bigorgne C, Lahet C, Cochet G, Bagot M et al.
Cutaneous T-cell inﬁltrates: analysis of T-cell receptor gamma gene rearrange-
ment by polymerase chain reaction and denaturing gradient gel electrophoresis.
Blood 1995; 86: 305–310.
12 Greiner TC, Raffeld M, Lutz C, Dick F, Jaffe ES. Analysis of T cell receptor-gamma
gene rearrangements by denaturing gradient gel electrophoresis of GC-clamped
polymerase chain reaction products. Correlation with tumor-speciﬁc sequences.
Am J Pathol 1995; 146: 46–55.
13 Dippel E, Assaf C, Hummel M, Schrag HJ, Stein H, Goerdt S et al. Clonal T-cell
receptor gamma-chain gene rearrangement by PCR-based GeneScan analysis in
advanced cutaneous T-cell lymphoma: a critical evaluation. J Pathol 1999; 188:
146–154.
14 Assaf C, Hummel M, Dippel E, Goerdt S, Mu¨ller HH, Anagnostopoulos I et al. High
detection rate of T-cell receptor beta chain rearrangements in T-cell lympho-
proliferations by family speciﬁc polymerase chain reaction in combination with
the GeneScan technique and DNA sequencing. Blood 2000; 96: 640–646.
15 Van Dongen JJ, Langerak AW, Bru¨ggemann M, Evans PA, Hummel M, Lavender FL
et al. Design and standardization of PCR primers and protocols for detection of
clonal immunoglobulin and T-cell receptor gene recombinations in suspect
lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936.
Leukemia 2003; 17: 2257–2317.
16 Bru¨ggemann M, White H, Gaulard P, Garcia-Sanz R, Gameiro P, Oeschger S et al.
Powerful strategy for PCR-based clonality assessment in T-cell malignancies.
Report of the BIOMED-2 Concerted Action BHM4-CT98-3936. Leukemia 2007; 21:
215–221.
17 Evans PAS, Pott C, Groenen PJTA, Salles G, Davi F, Berger F et al. Signiﬁcantly
improved PCR-based clonality testing in B-cell malignancies by use of multiple
immunoglobulin gene targets. Report of the BIOMED-2 Concerted Action BHM4-
CT98-3936. Leukemia 2007; 21: 207–214.
18 Langerak AW, Molina TJ, Lavender FL, Pearson D, Flohr T, Sambade C et al. PCR-
based clonality testing in tissue samples with reactive lymphoproliferations:
usefulness and pitfalls. A study from the BIOMED-2 Concerted Action BMH4-CT98-
3936. Leukemia 2007; 21: 222–229.
19 McClure RF, Kaur P, Pagel E, Ouillette PD, Holtegaard CE, Treptow CL et al. Vali-
dation of immunoglobulin gene rearrangement detection by PCR using com-
mercially available BIOMED-2 primers. Leukemia 2006; 20: 176–179.
20 Halldo´rsdo´ttir AM, Zehnbauer BA, Burack WR. Application of BIOMED-2 clonality
assays to formalin-ﬁxed parafﬁn embedded follicular lymphoma specimens:
superior performance of the IGK assays compared to IGH for suboptimal speci-
mens. Leuk Lymphoma 2007; 48: 1338–1343.
21 Liu H, Bench AJ, Bacon CM, Payne K, Huang Y, Scott MA et al. A practical strategy
for the routine use of BIOMED-2 PCR assays for detection of B- and T-cell clonality
in diagnostic haematopathology. Br J Haematol 2007; 138: 31–43.
22 Patel KP, Pan Q, Wang Y, Maitta RW, Du J, Xue X et al. Comparison of BIOMED-2
versus laboratory-developed polymerase chain reaction assays for detecting T-cell
receptor-gamma gene rearrangements. J Mol Diagn 2010; 12: 226–237.
23 Langerak AW, Groenen PJTA, Van Krieken JHJM, Van Dongen JJM. Immunoglo-
bulin/T-cell receptor clonality diagnostics. Exp Opin Med Diagn 2007; 1: 451–461.
24 Miller JE, Wilson SS, Jaye DL, Kronenberg M. An automated semiquantitative B
and T cell clonality assay. Mol Diagn 1999; 4: 101–117.
25 Greiner TC, Rubocki RJ. Effectiveness of capillary electrophoresis using ﬂuor-
escent-labeled primers in detecting T-cell receptor gamma gene rearrangements.
J Mol Diagn 2002; 4: 137–143.
26 Kuo FC, Hall D, Longtine JA. A novel method for interpretation of T-cell receptor
gamma gene rearrangement assay by capillary gel electrophoresis based on
normal distribution. J Mol Diagn 2007; 9: 12–19.
27 Lenze D, Mu¨ller HH, Hummel M. Considerations for the use of formalin-ﬁxed and
parafﬁn-embedded tissue specimens for clonality analysis. J Hematopathol 2012;
5: 27–34.
28 Groenen PJTA, Van Raaij A, Van Altena MC, Rombout PM, Van Krieken JHJM. A
practical approach to diagnostic Ig/TCR clonality evaluation in clinical pathology.
J Hematopathol 2012; 5: 17–25.
29 Beldjord K, Beldjor C, Macintyre EA, Even P, Sigaux F. Peripheral selection of
Vd1þ cells with restricted T cell receptor delta gene junctional repertoire in the
peripheral blood of healthy donors. J Exp Med 1993; 178: 121–127.
30 Groenen PJTA, Langerak AW, Van Dongen JJM, Van Krieken JHJM. Pitfalls in TCR
gene clonality testing: teaching cases. J Hematopathol 2008; 1: 97–109.
31 Diss TC, Molina TJ, Cabec¸adas J, Langerak AW. Molecular diagnostics in lym-
phoma: why, when and how to apply. Diagn Histopathol 2012; 18: 53–63.
32 Bonzheim I, Fro¨hlich F, Adam P, Colak S, Metzler G, Quintanilla-Martinez L et al. A
comparative analysis of protocols for detection of T cell clonality in formalin-ﬁxed,
parafﬁn-embedded tissue—implications for practical use. J Hematopathol 2012; 5:
7–16.
33 Gameiro P, Sebastiao M, Spetalen S, Gomes da Silva M, Cabecadas J. The added
value of immunoglobulin kappa light chain (IGK) gene rearrangement analysis in
suspected B-cell lymphomas: three illustrative cases. J Hematopathol 2012; 5: 45–56.
34 Gonzalez D, Rombout PM, Sarasquete ME, Villarese P, Wren D, Van Dongen JJM
et al. Capillary electrophoresis single strand conformation analysis (CE-SSCA)
for clonality detection in lymphoproliferative disorders. J Hematopathol 2012; 5:
83–89.
35 Langerak AW, Van Dongen JJM. Multiple clonal Ig/TCR products: implications for
interpretation of clonality ﬁndings. J Hematopathol 2012; 5: 35–43.
36 Rothberg PG, Langerak AW, Verhaaf B, Van Dongen JJM, Burack WR, Johnson MD
et al. Clonal antigen receptor gene PCR products outside the expected size range.
J Hematopathol 2012; 5: 57–67.
37 Sproul AM, Goodlad JR. Clonality testing of cutaneous lymphoid inﬁltrates:
practicalities, pitfalls and potential uses. J Hematopathol 2012; 5: 69–82.
38 Payne K, Wright P, Grant JW, Huang Y, Hamoudi R, Bacon CM et al. BIOMED-2 PCR
assays for IGK gene rearrangements are essential for B-cell clonality analysis in
follicular lymphoma. Br J Haematol 2011; 155: 84–92.
39 Vargas RI, Felgar RE, Rothberg PG. Detection of clonality in lymphoproliferations
using PCR of antigen receptor genes: does size matter? Leuk Res 2008; 32:
335–338.
40 Liao YL, Chang ST, Kuo SY, Lin SH, Chen CK, Chang KM et al. Angioimmunoblastic
T-cell lymphoma of cytotoxic T-cell phenotype containing a large B-cell
proliferation with an undersized B-cell clonal product. Appl Immunohistochem Mol
Morphol 2010; 18: 185–189.
41 Goossens T, Klein U, Ku¨ppers R. Frequent occurrence of deletions and duplica-
tions during somatic hypermutation: implications for oncogene translocations
and heavy chain disease. Proc Natl Acad Sci USA 1998; 95: 2463–2468.
42 Langerak AW. Undersized, oversized? It is not one-size-ﬁts-all in lymphoid clon-
ality detection. Leukemia Res 2008; 32: 203–204.
43 Sanchez ML, Almeida J, Gonzalez D, Gonzalez M, Garcia-Marcos MA, Balanzategui
A et al. Incidence and clinicobiologic characteristics of leukemic B-cell chronic
lymphoproliferative disorders with more than one B-cell clone. Blood 2003; 102:
2994–3002.
44 Sanchez ML, Almeida J, Lopez A, Sayagues JM, Rasillo A, Sarasquete EA et al.
Heterogeneity of neoplastic cells in B-cell chronic lymphoproliferative disorders:
EuroClonality/BIOMED-2 guidelines
AW Langerak et al
2170
Leukemia (2012) 2159 – 2171 & 2012 Macmillan Publishers Limited
biclonality versus intraclonal evolution of a single tumor cell clone. Haematologica
2006; 91: 331–339.
45 Nam-Cha SH, San-Milla´n B, Mollejo M, Garcı´a-Cosio M, Garijo G, Gomez M et al.
Light-chain-restricted germinal centres in reactive lymphadenitis: report of eight
cases. Histopathology 2008; 52: 436–444.
46 Harris S, Bruggemann M, Groenen PJTA, Schuuring E, Langerak AW, Hodges E.
Clonality analysis in lymphoproliferative disease using the BIOMED-2 multiplex
PCR protocols; experience from the EuroClonality group EQA scheme. J Hemato-
pathol 2012; 5: 91–98.
47 Szczepan´ski T, Beishuizen A, Pongers-Willemse MJ, Ha¨hlen K, Van Wering ER,
Wijkhuijs AJ et al. Cross-lineage T cell receptor gene rearrangements occur in
more than ninety percent of childhood precursor-B acute lymphoblastic leuke-
mias: alternative PCR targets for detection of minimal residual disease. Leukemia
1999; 13: 196–205.
48 Rombout PDM, Diss TC, Hodges E, Hummel M, Van Dongen JJM, Langerak AW
et al. The EuroClonality website: information, education and support on clonality
testing. J Hematopathol 2012; 5: 99–103.
This work is licensed under the Creative Commons Attribution-
NonCommercial-No Derivative Works 3.0 Unported License. To view a
copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/
EuroClonality/BIOMED-2 guidelines
AW Langerak et al
2171
& 2012 Macmillan Publishers Limited Leukemia (2012) 2159 – 2171
